Last reviewed · How we verify
diffuse large B-cell lymphoma (DLBCL) not otherwise specified
Approved treatments
- Zynlonta · ADC Therapeutics SA
Zynlonta works by binding to a specific target on cancer cells, marking them for destruction. - Kymriah · Novartis Pharmaceuticals Corporation
Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- diffuse large B-cell lymphoma (DLBCL) not otherwise specified patent landscape — cliff calendar, originator estates, attackable patents
- diffuse large B-cell lymphoma (DLBCL) not otherwise specified treatment landscape brief
- diffuse large B-cell lymphoma (DLBCL) not otherwise specified treatment updates RSS
Frequently asked questions about diffuse large B-cell lymphoma (DLBCL) not otherwise specified
What drugs treat diffuse large B-cell lymphoma (DLBCL) not otherwise specified?
Tracked treatments include Zynlonta, Kymriah.
What is the treatment for diffuse large B-cell lymphoma (DLBCL) not otherwise specified?
Standard treatment for diffuse large B-cell lymphoma (DLBCL) not otherwise specified includes Zynlonta, Kymriah. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: diffuse large B-cell lymphoma (DLBCL) not otherwise specified patent cliff · diffuse large B-cell lymphoma (DLBCL) not otherwise specified CI report
- Treatment: Zynlonta · ADC Therapeutics SA
- Treatment: Kymriah · Novartis Pharmaceuticals Corporation
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing